Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
Iyas Daghlas, Dipender Gill/LinkedIn; Marta Pérez Alcántara/Wellcome Sanger Institute
Mar 7, 2026, 16:05

Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis

Iyas Daghlas, Vascular Neurology Fellow and Stroke Researcher at the University of California, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Excited to share our new publication in Neurology: ‘Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.’

Cerebral venous thrombosis (CVT) is a rare form of stroke treated with anticoagulation.

Despite widespread off-label direct oral anticoagulant (DOAC) use, no adequately powered RCT has demonstrated DOAC efficacy, and many patients continue to be treated with warfarin, which carries substantial major bleeding risk.

We addressed this evidence gap by examining effects of naturally randomized genetic variants perturbing the protein targets of established (F2+F10) and emerging (F11) DOACs.

See Table 1 for a cool demonstration of the natural allocation of covariates/confounders across genotypes, mimicking an RCT ‘Table 1.’

We found evidence that genetically reduced levels of thrombin, factor Xa, and factor XI are associated with reduced CVT risk – see forest plot!

What this means:

  • FXI inhibitors (milvexian, asundexian, etc) are among the most actively investigated therapeutic targets in thrombosis today, with multiple Phase III trials underway. Our data provide the first human genetic evidence supporting repurposing potential for CVT, a new indication for this drug class.
  • Human genetics supports efficacy for established DOAC protein targets (thrombin and factor Xa) in reducing CVT risk
  • These data support the notion that, in general, therapeutics that are effective for venous thromboembolism will likely also work for CVT

Appreciate collaborators Marta Pérez Alcántara and Dipender Gill!”

Title: Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis. A Mendelian Randomization Study

Authors: Iyas Daghlas, Marta Pérez Alcántara, Dipender Gill

Read the Full Article on Neurology

Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis

Stay updated on all scientific advances with Hemostasis Today.

Cerebral Venous Thrombosis CVT Dipender Gill DOACs Health Hematology Hemostasis Hemostasis News Hemostasis Today Iyas Daghlas Marta Pérez Alcántara Medicine Neurology thrombosis
NewsFeed